R
4.10
-0.08 (-1.91%)
| Previous Close | 4.18 |
| Open | 4.21 |
| Volume | 23,333,506 |
| Avg. Volume (3M) | 23,958,413 |
| Market Cap | 2,137,177,216 |
| Price / Sales | 38.57 |
| Price / Book | 2.08 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -1,297.85% |
| Diluted EPS (TTM) | -1.80 |
| Quarterly Revenue Growth (YOY) | 6.90% |
| Total Debt/Equity (MRQ) | 9.95% |
| Current Ratio (MRQ) | 4.11 |
| Operating Cash Flow (TTM) | -388.83 M |
| Levered Free Cash Flow (TTM) | -204.88 M |
| Return on Assets (TTM) | -38.51% |
| Return on Equity (TTM) | -86.10% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Recursion Pharmaceuticals, Inc. | Bullish | Mixed |
AIStockmoo Score
0.4
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 0.38 |
|
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.78% |
| % Held by Institutions | 69.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kinnevik Ab (Publ) | 30 Sep 2025 | 13,434,171 |
| Mic Capital Management Uk Llp | 30 Sep 2025 | 9,644,032 |
| Data Collective Iv Gp, Llc | 30 Sep 2025 | 5,941,120 |
| 52 Weeks Range | ||
| Median | 11.00 (168.29%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 17 Dec 2025 | 11.00 (168.29%) | Buy | 4.68 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |